This is the authors' abstract. We don't add key points for this paper.
Enzalutamide with ADT significantly reduced the risk of metastatic progression or death over time versus placebo plus ADT in men with mHSPC, including those with low-volume disease and/or prior docetaxel, with a safety analysis that seems consistent with the safety profile of enzalutamide in previous clinical trials in castration-resistant prostate cancer.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Armstrong et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: